Roche Gains Rights to Hanmi Obesity Drug That Reduces Fat, Preserves Muscle
Hanmi Pharmaceutical’s drug is designed to activate a receptor in skeletal muscle to both increase muscle mass and reduce fat. This engineered peptide gives Roche a clinical-stage asset that addresses a different target than the other obesity drugs in its pipeline.
presented by
A Partnership-driven Approach to Waste and Abuse Prevention
Discover how payers can shift from costly post-payment recovery to intentional prevention through data-driven oversight, accountability, and partnership.
Why Psychiatry Can’t Ignore Metabolic Health Anymore
Metabolic psychiatry has moved past being a fringe theory. It is a practical, evidence-based necessity for a field that has been stagnant for too long.
Ambient Scribes Improve Clinician Retention, Cleveland Clinic Research Shows
A new paper shows Cleveland Clinic's AI scribe rollout is paying dividends in clinician satisfaction and retention. These are key metrics for hospitals to track, given they spend millions on recruitment and retention efforts amid an ongoing workforce crisis.
Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs
Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness. A Phase 2/3 study failed earlier this year, but Abcuro saw positive trends in patients with less severe disease.